At 2.5% CAGR, the South & Central America Anti-Infective Agents Market is  projected to be worth US$ 6,498.70 Million by 2028, says Business Market Insights

According to Business Market Insights’ research, the South & Central America anti-infective agents market was valued at US$ 5,713.39 million in 2022 and is expected to reach US$ 6,498.70 million by 2028, registering an annual growth rate of 2.5% from 2022 to 2028. Develoment of new anti-infective agents and surging investments in R&D activities in pharmaceutical sector are the critical factors attributed to the market expansion.

Developments in the medical devices industry have motivated the existing players and new entrants to introduce their novel products in the market. Additionally, there have been lots of developments in techniques involved in medical examinations. The use of illuminating light sources with longer shelf life in gynecological procedures is encouraging market players to develop and introduce anti-infective agents. TLRs, or toll-like receptors, are important components of innate immunity. They have the ability to detect a variety of microbes, including viruses, bacteria, fungus, and protozoa. Innate immunological reactions can directly influence adaptive immune reactions. Therefore, TLRs are considered therapeutic targets for autoimmune diseases, including autoimmune disorders, allergies, sepsis, and cancer. Two COVID-19 vaccines were created using mRNA technology (Pfizer-BioNTech35 and Moderna36), demonstrating safety and high efficacy. These vaccines currently have conditional marketing authorization from the European Medicines Agency (EMA) and emergency use authorization (EUA) from the US Food and Drug Administration (FDA). Such developments are expected to present lucrative opportunities for the growth of the anti-infective agent market in the years to come.

On the contrary, emergence of anti-infective drugs resistance and their various side effects hurdles the growth of South & Central America anti-infective agents market.

Based on type, the market is segmented into anti-bacterial, anti-viral, anti-fungal, and others. The anti-viral segment held the largest market share of 48.1% in 2022 with a revenue of US$ 2,748.92 million. Further, it is going to reach US$ 3,081.96 million by 2028 at  decent CAGR of 1.9% during the forecasted period.

Based on range, the anti-infective agents market sphere is bifurcated into broad spectrum and narrow spectrum. The former held 67.7% market share in 2022, amassing US$ 3,868.81 million. It is projected to garner US$ 4,360.67 million by 2028 to expand at 2.0% CAGR during 2022–2028.

Based on route of administration, the market is segmented into topical, oral, IV, and others. With 49.8% share IV segment dominated the market in 2022. It accrued US$ 2,845.47 million in 2022 and is estimated to reach by US$ 3,203.08 million by 2028 at a CAGR of 2.0% during 2022-2028.

Based on indication, the market is segmented into HIV, tuberculosis, respiratory infection, pneumonia, and others. The others segment held the largest market share of 38.8% in 2022 with a revenue of US$ 2,219.09 million. Further, it is going to reach US$ 2,430.63 million by 2028 at  decent CAGR of 1.5% during the forecasted period.   

Based on distribution channel, the market is segmented into hospital pharmacies, specialty pharmacies, e-commerce, and others. With 44.9% share of the domain, the hospital pharmacies segment dominated the market in 2022. It accrued US$ 2,563.03 million in 2022 and is estimated to generate US$ 2,908.30 million by 2028 to grow at a CAGR of 2.1% over the forecast period.

Our country analysis states that Brazil captured 45.6% market share in 2022. It was assessed at US$ 2,603.02 million in 2022 and is likely to hit US$ 2,991.91 million by 2028, exhibiting a CAGR of 2.3% during the forecast period.

Key players dominating the South & Central America anti-infective agents market are Abbott; Allergan Plc.; Astellas Pharma Inc.; Bayer AG; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; GlaxoSmithKline plc.; Merck & Co., Inc.; and Novartis AG are among others.    

Few of the recent key developments among the top market players are listed below:

• In April 2021, Abbott launched adult vaccination program for flu, typhoid, and more vaccines to safeguard people's health. The program aimed to create awareness regarding immunization in adult populations.

• In January 2021, Merck confirmed an agreement with UNICEF to establish the world’s first global Ebola vaccine stockpile with ERVEBO® (Ebola Zaire Vaccine, Live). ERVEBO is a vaccine indicated for the prevention of disease caused by Zaire ebolavirus in individuals 18 years of age and older. 

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com